. "2" . "RIV/00064165:_____/12:13017!RIV13-MZ0-00064165" . . "Biguanidy jsou l\u00E9ky ur\u010Den\u00E9 pro terapii hyperglykemie u diabetu 2. typu. V posledn\u00ED dob\u011B se ukazuje, \u017Ee nej\u010Dast\u011Bji p\u0159edepisovan\u00FD biguanid metformin vykazuje tak\u00E9 protin\u00E1dorov\u00FD \u00FA\u010Dinek. Jeho mo\u017En\u00E9 vyu\u017Eit\u00ED v protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B podporuj\u00ED epidemiologick\u00E9, preklinick\u00E9 a klinick\u00E9 studie. P\u0159\u00EDzniv\u00E9 ovlivn\u011Bn\u00ED karcinomu prsu a tlust\u00E9ho st\u0159eva by mohlo souviset s prim\u00E1rn\u00ED schopnost\u00ED metforminu sni\u017Eovat hladinu cirkuluj\u00EDc\u00EDho inzulinu, ale metformin m\u00E1 nepochybn\u011B i p\u0159\u00EDm\u00FD cytostatick\u00FD efekt, kter\u00FD se uskute\u010D\u0148uje prost\u0159ednictv\u00EDm inhibice mTOR (mammalian target of rapamycin) sign\u00E1ln\u00ED dr\u00E1hy a blok\u00E1dou synt\u00E9zy protein\u016F. Vyu\u017Eit\u00ED metforminu v protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B nebo chemoprevenci n\u00E1dor\u016F ale uk\u00E1\u017Ee teprve budoucnost." . "Biguanidy jsou l\u00E9ky ur\u010Den\u00E9 pro terapii hyperglykemie u diabetu 2. typu. V posledn\u00ED dob\u011B se ukazuje, \u017Ee nej\u010Dast\u011Bji p\u0159edepisovan\u00FD biguanid metformin vykazuje tak\u00E9 protin\u00E1dorov\u00FD \u00FA\u010Dinek. Jeho mo\u017En\u00E9 vyu\u017Eit\u00ED v protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B podporuj\u00ED epidemiologick\u00E9, preklinick\u00E9 a klinick\u00E9 studie. P\u0159\u00EDzniv\u00E9 ovlivn\u011Bn\u00ED karcinomu prsu a tlust\u00E9ho st\u0159eva by mohlo souviset s prim\u00E1rn\u00ED schopnost\u00ED metforminu sni\u017Eovat hladinu cirkuluj\u00EDc\u00EDho inzulinu, ale metformin m\u00E1 nepochybn\u011B i p\u0159\u00EDm\u00FD cytostatick\u00FD efekt, kter\u00FD se uskute\u010D\u0148uje prost\u0159ednictv\u00EDm inhibice mTOR (mammalian target of rapamycin) sign\u00E1ln\u00ED dr\u00E1hy a blok\u00E1dou synt\u00E9zy protein\u016F. Vyu\u017Eit\u00ED metforminu v protin\u00E1dorov\u00E9 l\u00E9\u010Db\u011B nebo chemoprevenci n\u00E1dor\u016F ale uk\u00E1\u017Ee teprve budoucnost."@cs . "Metformin \u2013 nov\u00E1 hv\u011Bzda onkologick\u00E9 l\u00E9\u010Dby?"@cs . . "Metformin \u2013 nov\u00E1 hv\u011Bzda onkologick\u00E9 l\u00E9\u010Dby?"@cs . . "Metformin \u2013 a new star in cancer treatment?"@en . "http://www.onkologiecs.cz/pdfs/xon/2012/02/09.pdf" . "Tesa\u0159ov\u00E1, Petra" . . "Metformin \u2013 nov\u00E1 hv\u011Bzda onkologick\u00E9 l\u00E9\u010Dby?" . . "CZ - \u010Cesk\u00E1 republika" . . . . "3"^^ . . "[14F385FE5DDA]" . . "1802-4475" . . "1"^^ . "Metformin, an oral biguanide antidiabetic drug, is the most widely prescribed agent for treatment of type 2 diabetes. The drug mainly works by lowering glucose production by the liver, and thus lowering fasting blood glucose. Metformin acts as an insulin sensitizer, which leads to inhibition of gluconeogenesis in the liver, and has been found to be beneficial especially in overweight patients with diabetes. Metformin use has been postulated to contribute to a reduced risk of pancreatic, prostate, ovarian, and breast cancers. Metformin' s mechanism of action was examined recently and determined to be initiated by metformins role as an adenosine 5'-mono-phosphate\u2013 activated protein kinase (AMPK) activator through a tumor suppressor protein kinase known as LKB-1, which regulates AMPK levels. Activation of AMPK has been shown to suppress the mammalian target of the rapamycin (mTOR) signaling pathway, leading to antiproliferative and antiangiogenic effects."@en . . "Metformin \u2013 a new star in cancer treatment?"@en . "V" . . "6" . . "RIV/00064165:_____/12:13017" . "149676" . "1"^^ . "Onkologie" . "Metformin \u2013 nov\u00E1 hv\u011Bzda onkologick\u00E9 l\u00E9\u010Dby?" . "Cancer; diabetes mellitus; metformin; mTOR; AMPK"@en . . .